ImmunityBio

CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...

CULVER CITY, Calif., May 19, 2026 ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its...

CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...